Company news

Kymera Therapeutics, Inc. news in 2021

Kymera Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day

December 15, 2021

Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting

December 12, 2021

Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical Operations

December 5, 2021

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413

November 29, 2021

Kymera Therapeutics to Host Virtual R&D Day on December 16, 2021

November 16, 2021

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

November 11, 2021

Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update

November 9, 2021

Kymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting and the 63rd American Society of Hematology (ASH) Annual Meeting

November 3, 2021

Kymera Therapeutics to Participate in Upcoming Fourth Quarter Investor Conferences

October 31, 2021

Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers

October 26, 2021

Kymera to Hold Webcast and Conference Call Discussing Data from its KT-474 Phase 1 Trial to Be Presented at the 4th Annual Targeted Protein Degradation Summit on October 27th

October 19, 2021

Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit

October 12, 2021

Kymera Therapeutics to Present at Upcoming September Investor Conferences

September 1, 2021

Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update

August 5, 2021

Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality

July 28, 2021

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum

July 11, 2021

Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

July 5, 2021

Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

June 29, 2021

Kymera Therapeutics Announces Proposed Public Offering of Common Stock

June 27, 2021

Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism

June 27, 2021

Kymera Therapeutics Presents New Preclinical Data for its IRAKIMiD Degrader KT-413 Demonstrating Strong Antitumor Activity as Both Monotherapy and in Combination in MYD88-mutant Lymphoma Models

June 20, 2021

Kymera Therapeutics Appoints Elaine Caughey, MBA, as Chief Business Officer

June 20, 2021

Kymera Therapeutics to Present New Data Demonstrating both Single-agent and Combination Regressions in MYD88-mutant Lymphoma Preclinical Models with IRAKIMiD Degrader KT-413 at 16th ICML Meeting

June 8, 2021

Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

June 1, 2021

Kymera Therapeutics Presents New Data Demonstrating Proof-of-Degradation Using Novel Tissue-Restricted E3 Ligase

May 25, 2021

Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting

May 9, 2021

Kymera Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update

May 5, 2021

Kymera Therapeutics Appoints Juliet Williams, PhD, as Senior Vice President, Head of Biology

May 4, 2021

Kymera Therapeutics to Present at Upcoming May Investor Conferences

May 3, 2021

Kymera Therapeutics to Present New In Vivo Data Demonstrating the Broad Anti-Inflammatory Activity of its IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting

May 2, 2021

Kymera Therapeutics Presents Positive Late-Breaking Data from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology 2021 Annual Meeting

May 2, 2021

Kymera Therapeutics Honored by Boston Business Journal as a 2021 Best Places to Work Company

April 18, 2021

Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021

April 9, 2021

Kymera Therapeutics to Present New Results from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology (SID) 2021 Annual Meeting

April 8, 2021

Kymera Therapeutics Appoints Elena Ridloff, CFA, to Board of Directors

March 15, 2021

Kymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update

March 10, 2021

Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases

March 1, 2021

Kymera Therapeutics to Present at Upcoming March Investor Conferences

February 24, 2021

Kymera Therapeutics to Present at Upcoming February Investor Conferences

February 3, 2021

Kymera Therapeutics Strengthens Leadership with Key Appointments and Promotions

February 2, 2021

Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines Company

January 11, 2021

Kymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021

January 4, 2021

Decks in 2021